Nanoclusters compositions and methods

Patent metadata

Field	Value
Publication number	US-9278069-B2
Application number	US-201414535177-A
Country	US
Kind code	B2
Filing date	Nov 6, 2014
Priority date	Dec 16, 2005
Publication date	Mar 8, 2016
Grant date	Mar 8, 2016

Abstract

Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm.

First claim

What is claimed is:

1. A method comprising administering to a subject a composition, the composition comprising nanocluster comprised of a core of nanoparticles arranged such that the surface of the nanoparticles contact one another, the nanoparticles comprise an active ingredient, wherein the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm.

2. The method of claim 1 , further comprising determining if a subject is in need of treatment.

3. The method of claim 1 , wherein the active ingredient is an anti-inflammatory compound, a bronchodilator, an antimicrobial, a vaccine, an analgesic, an anxiolytic, a hypnotic, a vasodilator, a cytotoxic agent, an opiod, an anti-cancer agent, DNA, RNA, budesonide, vancomycin, moxifloxacin, mometazone, epinephrine, 13 C labeled urea, atropine, or diatrizoic acid.

4. The method of claim 3 wherein the subject has a medical condition that is treated with at least one of the active ingredients selected from the group consisting of an anti-inflammatory compound, a bronchodilator, an antimicrobial, a vaccine, an analgesic, an anxiolytic, a hypnotic, a vasodilator, a cytotoxic agent, an opiod, an anti-cancer agent, DNA, RNA, budesonide, vancomycin, moxifloxacin, mometazone, epinephrine, 13 C labeled urea, atropine, or diatrizoic acid.

5. The method of claim 1 , wherein the composition is formulated as a dry powder, a suspension, an aerosol, a spray, a tablet, or a liquid.

6. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the nanoparticles consists essentially of the active ingredient.

8. The method of claim 1 , wherein the step of administering the composition is performed by topical administration.

9. The method of claim 1 , wherein the step of administering the composition is performed by nasal administration.

10. The method of claim 1 , wherein the step of administering the composition is performed through medical tubing.

11. The method of claim 1 , wherein the step of administering the composition is performed by oral administration.

12. The method of claim 1 , wherein the step of administering the composition is performed by injection.

13. The method of claim 1 , wherein the step of administering the composition is performed by nebulization.

14. The method of claim 1 , wherein the step of administering the composition is performed by a dry powder inhaler.

15. The method of claim 1 , wherein the step of administering the composition is performed by a pressurized metered dose inhaler.

16. The method of claim 12 , wherein the injection is intravitreal or intraocular.

17. The method of claim 1 , wherein the composition is formulated as eye drops.

18. The method of claim 17 , wherein the step of administering the composition is performed by applying the eye drops to the subject's eyes.

19. The method of claim 17 , wherein the active ingredient is an antibiotic.

20. The method of claim 17 , wherein the active ingredient is a non-steroidal anti-inflammatory drug.

Assignees

• Univ Kansas

Inventors

• Berkland Cory J
• Shi Lianjun
• El Gendy Nashwa
• Plumley Carl
• Bailey Mark

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K9/5115

  Inorganic compounds · CPC title

• A61K9/14 Primary

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title

• A61M2202/064

  Powder · CPC title